Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-05-31, Stock:NVS, The news for the past five days is as follows:
2018-05-23: NEWS1: Should You Hold Momenta (MNTA) Stock in Your Portfolio?.NEWS2: Should You Hold Momenta (MNTA) Stock in Your Portfolio?.NEWS3: Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis.NEWS4: Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis.NEWS5: Why AveXis chose Durham for its 200-job expansion.NEWS6: Should You Expect Novartis AG (VTX:NOVN) To Continue Delivering An ROE Of 11.33%?.NEWS7: The Swiss Stock Market Pulled Back On Broad Weakness.NEWS8: The Swiss Stock Market Pulled Back On Broad Weakness.
2018-05-24: NEWS1: Is Genome Editing the Next Biotech Breakthrough?.NEWS2: Is Genome Editing the Next Biotech Breakthrough?.NEWS3: FDA Confirms September Action Date for Teva's Migraine Drug.NEWS4: FDA Confirms September Action Date for Teva's Migraine Drug.NEWS5: Novartis Gets Approval for Remicade Biosimilar in Europe.NEWS6: Novartis Gets Approval for Remicade Biosimilar in Europe.NEWS7: FDA Confirms September Action Date for Teva&apos;s Migraine Drug.NEWS8: bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA.NEWS9: bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA.NEWS10: Noteworthy ETF Inflows: VXUS, NSRGY, NVS, RY.NEWS11: Noteworthy ETF Inflows: VXUS, NSRGY, NVS, RY.NEWS12: Is This Little Biotech the Best Migraine Stock to Buy Now?.NEWS13: Is This Little Biotech the Best Migraine Stock to Buy Now?.NEWS14: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for May 25, 2018.NEWS15: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for May 25, 2018.NEWS16: Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings.NEWS17: The Swiss Stock Market Finished Lower After Early Gains Erode.NEWS18: The Swiss Stock Market Finished Lower After Early Gains Erode.
2018-05-25: NEWS1: Teva’s Fremanezumab Gets September Action Date from FDA.NEWS2: Eisai and Merck Announce Update on Lenvatinib sNDA Review.NEWS3: Eisai and Merck Announce Update on Lenvatinib sNDA Review.NEWS4: This Collaboration Is Expected to Boost Merck’s Long-Term Growth.NEWS5: European ADRs Move Lower in Friday Trading.NEWS6: European ADRs Move Lower in Friday Trading.NEWS7: Morning Movers: Foot Locker Soars on Earnings, Gap Slumps.NEWS8: Morning Movers: Foot Locker Soars on Earnings, Gap Slumps.NEWS9: The Swiss Stock Market Slipped Into The Red After Erasing Early Gains.NEWS10: The Swiss Stock Market Slipped Into The Red After Erasing Early Gains.
2018-05-29: NEWS1: Roche's Tecentriq Study Meets Co-Primary Endpoints for NSCLC.NEWS2: Roche's Tecentriq Study Meets Co-Primary Endpoints for NSCLC.NEWS3: Novartis Enters Oversold Territory.NEWS4: Novartis Enters Oversold Territory.NEWS5: Analyzing Incyte’s Revenue Stream in Q1 2018.NEWS6: Teva (TEVA) Stock Up 17% YTD After a Dismal 2017: Here's Why.NEWS7: Teva (TEVA) Stock Up 17% YTD After a Dismal 2017: Here's Why.NEWS8: Morning Movers: Upgrades, Downgrades…and a Great Big Mess in Italy.NEWS9: Morning Movers: Upgrades, Downgrades…and a Great Big Mess in Italy.NEWS10: An Overview Merck’s Diabetes and Women’s Health Portfolios.NEWS11: Incyte’s Revenue Trend in Q1 2018.NEWS12: The Swiss Stock Market Pulled Back On Broad Weakness.NEWS13: The Swiss Stock Market Pulled Back On Broad Weakness.
2018-05-30: NEWS1: Avenatti drops bid to represent Stormy Daniels in Trump lawyer Michael Cohen's case.NEWS2: Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan.NEWS3: Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan.NEWS4: Michael Cohen's lawyers accuse Stormy Daniels' attorney of 'drive-by shooting' in bank record dump.NEWS5: Incyte’s Collaborations and Developments in Q1 2018.NEWS6: How Incyte’s Jakafi Performed in Q1 2018.NEWS7: The Swiss Stock Market Slid Further On Concerns Over Italy.NEWS8: The Swiss Stock Market Slid Further On Concerns Over Italy.NEWS9: A Look at Incyte’s Product Portfolio in May.NEWS10: [$$] Novartis Drug Promacta Gets FDA Priority Review for First-Line SAA.NEWS11: FDA Expedites Review Of Novartis' Promacta For First-line Severe Aplastic Anemia.NEWS12: FDA Expedites Review Of Novartis' Promacta For First-line Severe Aplastic Anemia.

Answer: Decrease